{
  "id": 109,
  "text": "GynecolOncol,2014,132（1）:7680.[]EVIEAVILUalyndsisislgsmgrmdin vical cancerrecurrencerisk:AnNRG/GOG ancillaryanalysis.GynecolOncol2021,162(3）:532-538.[6]HUNGENGWNtlfftivnsfquelhmradtnornmradat radiationaloneinaduvanteamentafterhysterectomyforcervicalcancerTheTARSphase3randomizedclinical trial.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: GynecolOncol,2014,132（1）:7680.[]EVIEAVILUalyndsisislgsmgrmdin vical cancerrecurrencerisk:AnNRG/GOG ancillaryanalysis.GynecolOncol2021,162(3）:532-538.[6]HUNGENGWNtlfftivnsfquelhmradtnornmradat radiationaloneinaduvanteamentafterhysterectomyforcervicalcancerTheTARSphase3randomizedclinical trial.\n\n<question>: ",
  "ChatGPT_response_0": "TARS 阶段3随机临床试验是一项对宫颈癌患者进行放疗和化疗联合治疗的临床试验。这种治疗方案被用于术后宫颈癌患者，旨在减少癌症的复发风险和提高患者的生存率。该临床试验的目的是评估放射治疗联合化疗在宫颈癌治疗中的有效性和安全性，以指导临床实践中的治疗决策。通过这项研究，可以为医生和患者提供更多关于宫颈癌治疗的有效方法的信息。",
  "query": "什么是 TARS 阶段3随机临床试验？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 什么是 TARS 阶段3随机临床试验？\n\n<reference text>: GynecolOncol,2014,132（1）:7680.[]EVIEAVILUalyndsisislgsmgrmdin vical cancerrecurrencerisk:AnNRG/GOG ancillaryanalysis.GynecolOncol2021,162(3）:532-538.[6]HUNGENGWNtlfftivnsfquelhmradtnornmradat radiationaloneinaduvanteamentafterhysterectomyforcervicalcancerTheTARSphase3randomizedclinical trial.\n\n<reply>: ",
  "response": "TARS 阶段3随机临床试验是一项对宫颈癌患者进行放疗和化疗联合治疗的临床试验。这种治疗方案被用于术后宫颈癌患者，旨在减少癌症的复发风险和提高患者的生存率。该临床试验的目的是评估放射治疗联合化疗在宫颈癌治疗中的有效性和安全性，以指导临床实践中的治疗决策。通过这项研究，可以为医生和患者提供更多关于宫颈癌治疗的有效方法的信息。"
}